vs
Alpha Cognition Inc.（ACOG）与碧迪（BDX）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是Alpha Cognition Inc.的1880.4倍（$5.3B vs $2.8M）。碧迪净利率更高（7.3% vs -245.5%，领先252.7%）。碧迪自由现金流更多（$549.0M vs $-7.1M）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
ACOG vs BDX — 直观对比
营收规模更大
BDX
是对方的1880.4倍
$2.8M
净利率更高
BDX
高出252.7%
-245.5%
自由现金流更多
BDX
多$556.1M
$-7.1M
损益表 — Q4 2025 vs Q1 2026
| 指标 | | |
|---|---|---|
| 营收 | $2.8M | $5.3B |
| 净利润 | $-6.9M | $382.0M |
| 毛利率 | — | 45.9% |
| 营业利润率 | -283.7% | 10.5% |
| 净利率 | -245.5% | 7.3% |
| 营收同比 | — | -0.4% |
| 净利润同比 | — | 24.0% |
| 每股收益（稀释后） | $-0.10 | $1.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACOGBDX
| Q4 25 | $2.8M | $5.3B | ||
| Q3 25 | $2.8M | $5.9B | ||
| Q2 25 | $1.7M | $5.5B | ||
| Q1 25 | $2.9M | $5.3B | ||
| Q4 24 | — | $5.2B | ||
| Q3 24 | — | $5.4B | ||
| Q2 24 | — | $5.0B | ||
| Q1 24 | — | $5.0B |
净利润ACOGBDX
| Q4 25 | $-6.9M | $382.0M | ||
| Q3 25 | $-1.3M | $493.0M | ||
| Q2 25 | $-10.5M | $574.0M | ||
| Q1 25 | $-2.0M | $308.0M | ||
| Q4 24 | — | $303.0M | ||
| Q3 24 | — | $400.0M | ||
| Q2 24 | — | $487.0M | ||
| Q1 24 | — | $537.0M |
毛利率ACOGBDX
| Q4 25 | — | 45.9% | ||
| Q3 25 | — | 47.5% | ||
| Q2 25 | 96.7% | 47.8% | ||
| Q1 25 | 99.6% | 42.8% | ||
| Q4 24 | — | 43.2% | ||
| Q3 24 | — | 45.7% | ||
| Q2 24 | — | 46.2% | ||
| Q1 24 | — | 45.7% |
营业利润率ACOGBDX
| Q4 25 | -283.7% | 10.5% | ||
| Q3 25 | -187.0% | 11.8% | ||
| Q2 25 | -346.1% | 16.0% | ||
| Q1 25 | -125.9% | 10.4% | ||
| Q4 24 | — | 8.8% | ||
| Q3 24 | — | 11.4% | ||
| Q2 24 | — | 12.1% | ||
| Q1 24 | — | 14.5% |
净利率ACOGBDX
| Q4 25 | -245.5% | 7.3% | ||
| Q3 25 | -46.4% | 8.4% | ||
| Q2 25 | -632.7% | 10.4% | ||
| Q1 25 | -68.5% | 5.8% | ||
| Q4 24 | — | 5.9% | ||
| Q3 24 | — | 7.4% | ||
| Q2 24 | — | 9.8% | ||
| Q1 24 | — | 10.6% |
每股收益（稀释后）ACOGBDX
| Q4 25 | $-0.10 | $1.34 | ||
| Q3 25 | $-0.30 | $1.71 | ||
| Q2 25 | $-0.65 | $2.00 | ||
| Q1 25 | $-0.13 | $1.07 | ||
| Q4 24 | — | $1.04 | ||
| Q3 24 | — | $1.37 | ||
| Q2 24 | — | $1.68 | ||
| Q1 24 | — | $1.85 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $66.0M | $740.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $62.5M | $25.3B |
| 总资产 | $79.7M | $54.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACOGBDX
| Q4 25 | $66.0M | $740.0M | ||
| Q3 25 | $35.4M | $641.0M | ||
| Q2 25 | $39.4M | $735.0M | ||
| Q1 25 | $45.5M | $667.0M | ||
| Q4 24 | — | $711.0M | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $4.5B | ||
| Q1 24 | — | $2.3B |
股东权益ACOGBDX
| Q4 25 | $62.5M | $25.3B | ||
| Q3 25 | $33.9M | $25.4B | ||
| Q2 25 | $31.9M | $25.5B | ||
| Q1 25 | $40.8M | $25.2B | ||
| Q4 24 | — | $25.2B | ||
| Q3 24 | — | $25.9B | ||
| Q2 24 | — | $25.9B | ||
| Q1 24 | — | $25.6B |
总资产ACOGBDX
| Q4 25 | $79.7M | $54.8B | ||
| Q3 25 | $46.3M | $55.3B | ||
| Q2 25 | $45.1M | $54.9B | ||
| Q1 25 | $48.6M | $54.5B | ||
| Q4 24 | — | $54.7B | ||
| Q3 24 | — | $57.3B | ||
| Q2 24 | — | $55.6B | ||
| Q1 24 | — | $54.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.9M | $657.0M |
| 自由现金流经营现金流 - 资本支出 | $-7.1M | $549.0M |
| 自由现金流率自由现金流/营收 | -252.6% | 10.5% |
| 资本支出强度资本支出/营收 | 5.3% | 2.1% |
| 现金转化率经营现金流/净利润 | — | 1.72× |
| 过去12个月自由现金流最近4个季度 | $-20.7M | $2.6B |
8季度趋势，按日历期对齐
经营现金流ACOGBDX
| Q4 25 | $-6.9M | $657.0M | ||
| Q3 25 | $-5.3M | $1.4B | ||
| Q2 25 | $-6.1M | $1.2B | ||
| Q1 25 | $-2.0M | $164.0M | ||
| Q4 24 | — | $693.0M | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.3B | ||
| Q1 24 | — | $514.0M |
自由现金流ACOGBDX
| Q4 25 | $-7.1M | $549.0M | ||
| Q3 25 | $-5.4M | $1.0B | ||
| Q2 25 | $-6.1M | $1.0B | ||
| Q1 25 | $-2.1M | $35.0M | ||
| Q4 24 | — | $588.0M | ||
| Q3 24 | — | $882.0M | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $380.0M |
自由现金流率ACOGBDX
| Q4 25 | -252.6% | 10.5% | ||
| Q3 25 | -188.8% | 17.0% | ||
| Q2 25 | -370.9% | 19.0% | ||
| Q1 25 | -72.0% | 0.7% | ||
| Q4 24 | — | 11.4% | ||
| Q3 24 | — | 16.2% | ||
| Q2 24 | — | 22.4% | ||
| Q1 24 | — | 7.5% |
资本支出强度ACOGBDX
| Q4 25 | 5.3% | 2.1% | ||
| Q3 25 | 2.6% | 6.0% | ||
| Q2 25 | 0.5% | 3.2% | ||
| Q1 25 | 2.2% | 2.4% | ||
| Q4 24 | — | 2.0% | ||
| Q3 24 | — | 5.4% | ||
| Q2 24 | — | 3.6% | ||
| Q1 24 | — | 2.7% |
现金转化率ACOGBDX
| Q4 25 | — | 1.72× | ||
| Q3 25 | — | 2.75× | ||
| Q2 25 | — | 2.12× | ||
| Q1 25 | — | 0.53× | ||
| Q4 24 | — | 2.29× | ||
| Q3 24 | — | 2.94× | ||
| Q2 24 | — | 2.66× | ||
| Q1 24 | — | 0.96× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACOG
暂无分部数据
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
